Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
Jin-Ling Huo, Yatao Wang, Wen-Jia Fu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 99

Showing 1-25 of 99 citing articles:

Tumor microenvironment signaling and therapeutics in cancer progression
Anshika Goenka, Fatima Khan, Bhupender Verma, et al.
Cancer Communications (2023) Vol. 43, Iss. 5, pp. 525-561
Open Access | Times Cited: 115
Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors
Shovan Dutta, Anirban Ganguly, Kaushiki Chatterjee, et al.
Biology (2023) Vol. 12, Iss. 2, pp. 218-218
Open Access | Times Cited: 71
Cancer immune escape: the role of antigen presentation machinery
Anoop Kallingal, Mateusz Olszewski, Natalia Maciejewska, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 10, pp. 8131-8141
Open Access | Times Cited: 62
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
Firas Kreidieh, Hussein A. Tawbi
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 40
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
Lisa Kinget, Stefan Naulaerts, Jannes Govaerts, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1667-1679
Closed Access | Times Cited: 16
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors
Yi-Shan Teng, Sebastian Yu
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6805-6819
Open Access | Times Cited: 22
Regulatory T cells in immune checkpoint blockade antitumor therapy
An Zhang, Tao Fan, Yixiao Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Wonyoung Jo, Taejoon Won, Abdel Daoud, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Anna Fateeva, Kevinn Eddy, Suzie Chen
Cancers (2024) Vol. 16, Iss. 8, pp. 1571-1571
Open Access | Times Cited: 10
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Natalie Fuchs, Longfei Zhang, Laura Calvo‐Barreiro, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 68-68
Open Access | Times Cited: 8
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions
Grace m. Kuo, Ramhari Kumbhar, W. Frank Blair, et al.
Molecular Neurodegeneration (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Chin Sern Yiong, Tzu Ping Lin, Vivian Lim, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 17
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
Fuat Bicer, Catrina Kure, Anil A. Ozluk, et al.
Current Oncology (2023) Vol. 30, Iss. 11, pp. 9789-9812
Open Access | Times Cited: 16
Regulatory T cells in spondyloarthropathies: genetic evidence, functional role, and therapeutic possibilities
Stefano Rodolfi, Connor Davidson, Matteo Vecellio
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 7
Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy
Salima Shebbo, Najat Binothman, Manar Darwaish, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Varsha Godakhindi, Mubin Tarannum, Sudip Kumar Dam, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 20
Open Access | Times Cited: 7
Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy
Changhui Li, Xinyu Yu, Xinyan Han, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110750-110750
Open Access | Times Cited: 7
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Md Aslam Hossain
International Immunopharmacology (2024) Vol. 143, pp. 113365-113365
Closed Access | Times Cited: 7
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape
Giorgia Scafetta, Calogero D’Alessandria, Armando Bartolazzi
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 6
From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review
Moksada Regmi, Yingjie Wang, Weihai Liu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 6
LAG‐3 : recent developments in combinational therapies in cancer
Aude Chavanton, Flavie Mialhe, Jimena Abrey, et al.
Cancer Science (2024) Vol. 115, Iss. 8, pp. 2494-2505
Open Access | Times Cited: 6
Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology
Vincenzo Quagliariello, Margherita Passariello, Isabella Bisceglia, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 5
Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Mengyao Xu, Na Zeng, Chen‐Qian Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
Jiaman Du, Jiewen Fu, Wenqian Zhang, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 3
Open Access | Times Cited: 13
Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets
Tatiana Vilela, Sofia Valente, Jorge Correia, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189144-189144
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top